Long term survival, time to next treatment and CD30 expression in patients with advanced CD30<sup>+</sup> cutaneous T-cell lymphoma treated with Brentuximab vedotin - A monocentric retrospective analysis of twelve patients.

Gosmann, Janika; Stadler, Rudolf

Long term survival, time to next treatment and CD30 expression in patients with advanced CD30⁺ cutaneous T-cell lymphoma treated with Brentuximab vedotin - A monocentric retrospective analysis of twelve patients.

Gosmann, Janika; Stadler, Rudolf.

Afiliação

Gosmann J; University Clinic for Dermatology, Johannes Wesling Medical Centre, UKRUB, University of Bochum, Bochum, Germany.
Stadler R; University Clinic for Dermatology, Johannes Wesling Medical Centre, UKRUB, University of Bochum, Bochum, Germany.

J Dtsch Dermatol Ges ; 20(4): 514-517, 2022 04.

Article em En | MEDLINE | ID: mdl-35319153

Assuntos

Linfoma Cutâneo de Células T; Neoplasias Cutâneas; Brentuximab Vedotin/uso terapêutico; Humanos; Antígeno Ki-1; Linfoma Cutâneo de Células T/tratamento farmacológico; Linfoma Cutâneo de Células T/patologia; Estudos Retrospectivos; Neoplasias Cutâneas/tratamento farmacológico; Neoplasias Cutâneas/patologia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Linfoma Cutâneo de Células T Tipo de estudo: Observational_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google